News

U.S. FDA Orphan Drug Designation underscores darizmetinib’s potential to address a significant unmet need following liver resection Tuebingen, Germany, August 26, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to darizmetinib (formerly HRX215) for the

The collaboration will focus on non-adherence, missed appointments, and clinical trial retention. BRUSSELS, Belgium – June 23, 2026 – Cognivia announced a collaboration with Mayo Clinic aimed at advancing behavioral intelligence across clinical research and clinical care. Building on Cognivia’s behavioral intelligence capabilities and Mayo Clinic’s expertise in patient care and shared decisionmaking, the collaboration will initially focus on three important

Tuebingen, Germany, February 11, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinicalstage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the completion of the Phase Ib minor resection study of HRX-215. Five patients in the clinical trial were treated with HRX-215 for a period of 28 days after a minor liver resection (≤ 30%) due to liver

And continued progress of its alpestria-1 clinical phase 2 study in alport syndrome patient Vonafexor reversed a historical mean eGFR decline of -6.4 mL/min/1.73 m²/yr to a mean functional gain on-treatment of +4.8 mL/min/1.73 m²/yr from baseline 73% of patients maintained albuminuria reduction three months after treatment cessation consistent with a true disease-modifying effect Company plans to advance vonafexor to

And continued progress of its alpestria-1 clinical phase 2 study in alport syndrome patient Investment seen as further validation of the corporate nutrition benefit market and its ability to manage workforce health and costs. LISBON, Portugal, Sept. 16, 2025 /PRNewswire/  – Nutrium, an all-in-one corporate nutrition solution that helps millions of patients worldwide create personalized meal plans, track progress, manage chronic diseases,

And continued progress of its alpestria-1 clinical phase 2 study in alport syndrome patient ENYO completes €32 million Series C with new €6 million investment from Vesalius Biocapital IV New funds will support two additional clinical studies and expand preclinical research, including in ADPKD Topline results from its ALPESTRIA-1 Phase 2 trial of Vonafexor in Alport Syndrome confirmed for Q4